ACAD - Acadia raises 2025 NUPLAZID guidance to $665M-$690M as DAYBUE accelerates community uptake
2025-08-07 03:58:32 ET
More on Acadia Pharma
- ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript
- Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
- ACADIA Pharmaceuticals: Advancing On Several Fronts
- Acadia Pharma Q2 2025 Earnings Preview
- Acadia gets court approval related to Nuplazid patent